Monte Rosa Therapeutics Collaborated with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
- Monte Rosa Therapeutics will receive $50M up front and is eligible to receive ~$2B in future preclinical, clinical, commercial, and sales milestones along with tiered royalties
- Monte Rosa Therapeutics will be responsible for the discovery and preclinical activities against multiple select cancer and neurological diseases & holds full ownership of its pipeline programs while Roche will get the right for further preclinical and clinical development of the compounds
- The collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients
Ref: Globenewswire | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at email@example.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.